<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>374</serviceExecutionTime><Drug id="79686"><DrugName>SynCav</DrugName><DrugSynonyms><Name><Value>SynCav</Value></Name><Name><Value>gene therapy (neurodegenerative diseases), Raft Therapeutics</Value></Name></DrugSynonyms><CompanyOriginator id="1071732">Raft Therapeutics</CompanyOriginator><CompaniesSecondary><Company id="1071732">Raft Therapeutics</Company></CompaniesSecondary><CrossReferences><SourceEntity id="233" type="ciIndication"><TargetEntity id="10053643" type="MEDDRA"></TargetEntity><TargetEntity id="D019636" type="MeSH"></TargetEntity><TargetEntity id="-1502359765" type="omicsDisease"></TargetEntity><TargetEntity id="160" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="PTGT-04157" type="ciTarget"><TargetEntity id="565309138573" type="siTarget">Caveolin-1</TargetEntity><TargetEntity id="2247" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="233">Neurodegenerative disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="16558">Caveolin 1 stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="4778">Gene therapy</Action></ActionsSecondary><Technologies><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-08-18T05:46:20.000Z</LastModificationDate><ChangeDateLast>2014-02-18T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-25T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1071732" linkType="Company"&gt;Raft Therapeutics&lt;/ulink&gt; was investigating SynCav, a gene therapy that upregulates synaptic driven Caveolin-1 to  promote regeneration of neurons, for the potential treatment of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. In June 2012, the program was listed as being in preclinical development [&lt;ulink linkID="1310431" linkType="Reference"&gt;1310431&lt;/ulink&gt;]. However, in August 2012,   Raft Therapeutics was dissolved and all development by the company has been discontinued [&lt;ulink linkID="1525441" linkType="Reference"&gt;1525441&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By June 2012, data from the in vivo studies had demonstrated that SynCav reduced the loss of neurons in traumatic brain injury [&lt;ulink linkID="1310431" linkType="Reference"&gt;1310431&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1071732">Raft Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="233">Neurodegenerative disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-08-22T00:00:00.000Z</StatusDate><Source id="1525441" type="OTHER"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1071732">Raft Therapeutics</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="233">Neurodegenerative disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2012-06-21T00:00:00.000Z</StatusDate><Source id="1310431" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-04157"><Name>Caveolin 1</Name><SwissprotNumbers><Swissprot>P33724</Swissprot><Swissprot>P35431</Swissprot><Swissprot>P41350</Swissprot><Swissprot>P49817</Swissprot><Swissprot>P79132</Swissprot><Swissprot>Q03135</Swissprot><Swissprot>Q07DV9</Swissprot><Swissprot>Q07DX1</Swissprot><Swissprot>Q07DY2</Swissprot><Swissprot>Q07DZ2</Swissprot><Swissprot>Q07E02</Swissprot><Swissprot>Q07E25</Swissprot><Swissprot>Q07E38</Swissprot><Swissprot>Q07E49</Swissprot><Swissprot>Q09YH8</Swissprot><Swissprot>Q09YK1</Swissprot><Swissprot>Q09YN6</Swissprot><Swissprot>Q108U7</Swissprot><Swissprot>Q2IBA5</Swissprot><Swissprot>Q2IBC1</Swissprot><Swissprot>Q2IBD7</Swissprot><Swissprot>Q2IBF0</Swissprot><Swissprot>Q2IBG8</Swissprot><Swissprot>Q2QL79</Swissprot><Swissprot>Q2QL90</Swissprot><Swissprot>Q2QLB0</Swissprot><Swissprot>Q2QLC1</Swissprot><Swissprot>Q2QLF2</Swissprot><Swissprot>Q2QLG6</Swissprot><Swissprot>Q2QLH7</Swissprot><Swissprot>Q6B3Y2</Swissprot><Swissprot>Q6RVA9</Swissprot><Swissprot>Q94051</Swissprot><Swissprot>Q9YGM8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>